Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11613-11620

  García Vicente, Ana María ^a   Cruz Mora, Miguel Ángel ^b   León Martín, Antonio Alberto ^a   Muñoz Sánchez, María del Mar ^c   Relea Calatayud, Fernanda ^a   Van Gómez López, Ober ^a   Espinosa Aunión, Ruth ^d   Gonzalez Ageitos, Ana ^e   Soriano Castrejón, Ángel ^a  

^a University General Hospital   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c Virgen de la Luz Hospital   (Spain)

^d Pharmacy Department   (Spain)

^e H Ntra Sra del Prado   (Spain)

Author keywords

FDG; Glycolytic metabolism; Locally advanced breast cancer; Neoadjuvant chemotherapy response; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; FOLLOW UP; GLYCOLYSIS; HUMAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TUMOR INVASION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLYCOLYSIS; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927800420     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2495-7     Document Type: Article

References (29)

1. Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.
2. Oza AM, Tannock IF. Clinical relevance of breast cancer biology. Hematol Oncol Clin North Am. 1994;8:1–14.
3. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–88.
4. Koolen BB, Pengel KE, Wesseling J, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013;22:691–7.
5. García García-Esquinas MA, Arrazola García J, García-Sáenz JA, et al. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel. Rev Esp Med Nucl Imagen Mol. 2014;33:14–21.
6. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–9.
7. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806–14.
8. American Joint Committee on Cancer (AJCC) 7th edition. http://www.cancerstaging.org/staging/index.html.
9. 18F-fluorodesoxiglucosa. Rev Esp Med Nucl. 2009;28:85–9.
10. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66.
11. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.
12. García Vicente AM, Soriano Castrejón A, Cruz Mora MA, et al. Dual time point 2-deoxy-2-[18F] fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer. Rev Esp Med Nucl Image Mol. 2014;33:1–5.
13. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. Rev Esp Med Nucl. 2012;31:308–14.
14. 18F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors. Eur J Nucl Med Mol Imaging. 2013;40:72–9.
15. Zucchini G, Quercia S, Zamagni C, et al. Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer. 2013;49:1539–45.
16. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102:75–84.
17. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.
18. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.
19. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual 7th edition. 2010. Springer.
20. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neodjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.
21. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27.
22. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–44.
23. van Quarles Ufford HM, van Tinteren H, Stroobants SG, et al. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis. J Nucl Med. 2010;51:1507–16.
24. Buchbender C, Kuemmel S, Hoffmann O, et al. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. Acta Radiol. 2012;53:628–36.
25. Ueda S, Saeki T, Shigekawa T, et al. 18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol. 2012;17:276–82.
26. Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli M-C, et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat. 2012;131:517–25.
27. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. 18F-FDG PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–24.
28. Jung S-Y, Kim S-K, Nam B-H, et al. Prognostic impact of 18F FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. 2010; 17:247-53
29. Duch J, Fuster D, Muñoz M, et al. 18F-FDG PET/CT for the early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–57.